GLP-1 drugs carry risk of rare but serious eye condition – a physician studying these medicines explains the potential side effect — Live Feedhttps://www.live-feeds.com/feed/glp-1-drugs-carry-risk-of-rare-but-serious-eye-condition-a-physician-studying-these-medicines-explains-the-potential-sidContinuously updated, source-cited coverage. FDA Orders Eye Risk Warnings For GLP-1 Drugshttps://www.live-feeds.com/feed/glp-1-drugs-carry-risk-of-rare-but-serious-eye-condition-a-physician-studying-these-medicines-explains-the-potential-sidhttps://www.live-feeds.com/feed/glp-1-drugs-carry-risk-of-rare-but-serious-eye-condition-a-physician-studying-these-medicines-explains-the-potential-sid#u201402Sun, 15 Nov 2026 00:00:07 +0000Federal health regulators have ordered new warning labels for popular GLP-1 receptor agonist medications, citing a potential link to rare but severe eye conditions. Medications affected by the regulatory action include Ozempic, Wegovy, and Zepbound. The updated product warnings highlight a rare risk of vision loss and sudden blindness associated with the treatments. Physicians and researchers studying these medicines are explaining the mechanisms behind the potential side effects as patients and providers evaluate the updated safety information.Why it mattersGLP-1 receptor agonists are widely